MedTrace Logo

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

NCT01606709 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-11-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare gene expression profiles in endometrial biopsies during the window of implantation after triggers of oocyte maturation using GnRH agonist or hCG and compared with their natural cycles in order to identify genes that may be dysregulated in GnRH agonist-triggered cycles.

The investigators also intend to evaluate patients feeling of well being and physical quality of life after GnRH agonist trigger compared with hCG trigger.

Conditions

  • Endometrial Receptivity
  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

GnRH agonist

GnRH agonist 1mg one dose

DRUG

hCG

5,000 IU one dose

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • UConn Health

    lead OTHER

Principal Investigators

  • Lawrence Engmann, MD, MRCOG · UConn Health

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
33 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-12-31
Completion
2014-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01606709 on ClinicalTrials.gov